pharma
dog
News
when
Latest
Archive
by source
All Sources
Sources Page
Jobs
department
Clinical
Regulatory
Medical Affairs
Commercial
R&D / Discovery
Biostatistics / Data
Manufacturing / CMC
Market Access
therapeutic area
Oncology
Immunology
Neuroscience
Cardiovascular
Metabolic
Rare Disease
Infectious Disease
location & type
Remote Only
US Only
California
Massachusetts
Internships
Phase 3 Roles
All Jobs →
Drugs
by stage
Marketed
Phase 3
Phase 2
Phase 1
Preclinical
browse
Most catalysts
Recently active
All drugs →
Companies
Patent cliff
Calendar
what
Trial readouts
PDUFA dates
Approvals
Earnings
when
Upcoming
Month grid
Recently passed
◐
Sign In
Subscribe
home
jobs
news
search
Gene Therapy (AAV) · news · pharmadog
← back to Gene Therapy (AAV)
News · Gene Therapy (AAV)
527
stories
11d
FDA launches investigation of Novartis’ Zolgensma after cancer cases
endpoints
11d
STAT+: BIO joins the legal fight against Medicare pilot that ties drug prices to peer countries
stat
11d
STAT+: Failure of Novartis Lp(a) drug raises questions about cardiovascular strategy
stat
11d
STAT+: Despite Novo drug’s failure, cardiologists say they will still pursue anti-inflammatories
stat
12d
STAT+: Democrats’ midterm landslide spells relief for hospitals
stat
12d
Novartis reveals cancer cases possibly linked to gene therapy Zolgensma
biopharma dive
12d
STAT+: Up and down the ladder: The latest comings and goings
stat
12d
STAT+: New tumor cases show common gene therapy tool can come with risk
stat
12d
Forge’s Piteri-Molina on AI, Ohio and what’s next for gene therapy manufacturing
biospace
12d
STAT+: Amgen’s Repatha linked to fewer heart attacks
stat
12d
STAT+: Pharmalittle: We’re reading about a Novartis gene therapy, faster U.K. drug reviews, and more
stat
12d
Sarepta’s new CEO confident in clinical execution as DMD competitors close in
biospace
12d
Sarepta quits enrolling for confirmatory Phase 3 trial of Elevidys
endpoints
12d
Lilly, Hims reach GLP-1 deal; Alnylam sales chief to step down
biopharma dive
12d
There's more than one way to build a biotech
fiercebiotech
13d
MedWatch Alert: FDA Investigating Serious Risk of Malignancy Linked to Zolgensma Gene Therapy
fda medwatch
13d
STAT+: Pharma’s trade group spent heavily on search ads to sway public opinion
stat
13d
Seven new tumor cases reported among patients on Novartis' Zolgensma gene therapy
endpoints
13d
Child dies of measles in Wisconsin’s first such death since 1990
stat
13d
STAT+: Novartis cites cases of previously unknown tumors possibly tied to its SMA gene therapy
stat
13d
STAT+: Novartis cites cases of previously unknown tumors possibly tied to its SMA gene therapy
stat
13d
STAT+: Stunning $6M defamation verdict reverberates at MIT campus, global scientific community
stat
13d
Novartis confirms 9 reported cases of tumors in patients treated with Zolgensma
biospace
13d
STAT+: A possible comeback for a failed sickle cell gene therapy
stat
13d
Single-payer health care system proponents were thrown a big bone this election
stat
13d
STAT+: A closer look at ProMis Neurosciences and its Alzheimer’s drug
stat
14d
Q3 earnings roll on, FDA pushes rare disease, uniQure’s Huntington’s therapy reaches review
biospace
15d
Ultragenyx shrinks workforce and axes assets to halve R&D spend
fiercebiotech
15d
Ultragenyx to lay off 20% of employees, scrap a Wilson disease gene therapy
endpoints
15d
UniQure gets an FDA decision date; Teva scraps brain drug study
biopharma dive
← prev
page 3 of 18
next →